Clarifying IL-1/IL-6 mutual regulations and interactions in vivo, in patients with sJIA, may lead to a better understanding of disease pathogenesis and, possibly, of a way to predict response to treatments. This evidence concerns the gene IL6 and systemic-onset juvenile idiopathic arthritis.